Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by research analysts at ...
Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback